

New Zealand Data Sheet

1. PRODUCT NAME

TIVICAY dolutegravir 50 mg film-coated tablets

TIVICAY film-coated tablets contain dolutegravir (as dolutegravir sodium) which is an integrase inhibitor active against Human Immunodeficiency Virus (HIV).

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

TIVICAY is supplied as film-coated tablets each containing 52.6 mg of dolutegravir sodium, equivalent to 50 mg of dolutegravir free acid.

For the full list of excipients, see section 6.1 List of excipients.

3. PHARMACEUTICAL FORM

Film-coated tablets.

Yellow, film-coated, round, biconvex tablets, debossed with 'SV 572' on one side and '50' on the other side.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

TIVICAY is indicated for the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in adults and children over 12 years of age and weighing 40 kg or more (see Section 4.4 Special warnings and precautions for use).

4.2 Dose and method of administration

TIVICAY therapy should be initiated by a physician experienced in the management of HIV infection.

Dose

Adults

Patients infected with HIV-1 without resistance to the integrase class

The recommended dose of TIVICAY is 50 mg once daily.

Patients infected with HIV-1 with resistance to the integrase class (documented or clinically suspected)

The recommended dose of TIVICAY is 50 mg twice daily. The decision to use dolutegravir for such patients should be informed by the integrase resistance pattern (see section 5.1 Pharmacodynamic properties).

The following should be considered prior to initiating treatment with TIVICAY 50 mg twice daily:

- Reduced virologic response was observed in patients treated with TIVICAY 50 mg twice daily with an INI-resistance Q148H/K/R mutation plus 2 or more additional INI-resistance mutations including, but not limited to G140A/C/S, E138A/K/T, or L74I (see section 5.1 Pharmacodynamic properties).

Adolescents

In patients who have not previously been treated with an integrase inhibitor, (12 to less than 18 years of age and weighing greater than or equal to 40 kg) the recommended dose of TIVICAY is 50 mg once daily.

There are insufficient data to recommend a dose for TIVICAY in integrase inhibitor resistant children and adolescents under 18 years of age.

Paediatric population

There are insufficient safety and efficacy data available to recommend a dose for TIVICAY in children below age 12 or weighing less than 40 kg.

Special populations

Elderly

There are limited data available on the use of TIVICAY in patients aged 65 years and over. However, there is no evidence that elderly patients require a different dose than younger adult patients (see section 5.2 Pharmacokinetic properties – Special populations).

Renal impairment

No dosage adjustment is required in patients with mild, moderate or severe creatinine clearance (CrCl) <30 mL /min, not on dialysis) renal impairment. No data are available in patients receiving dialysis, although differences in pharmacokinetics are not expected in this population (see section 5.2 Pharmacokinetic properties – Special populations).

TIVICAY has been shown to decrease estimated creatinine clearance due to inhibition of tubular secretion of creatinine without affecting actual renal glomerular function. This effect should be considered when TIVICAY is co-administered with a drug that has dosing adjustment recommendations guided by estimated creatinine clearance.

Hepatic impairment

No dosage adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh grade A or B). No data are available in patients with severe hepatic impairment (Child-Pugh grade C) (see section 5.2 Pharmacokinetic properties – Special populations).

Method of administration

TIVICAY can be taken with or without food.

4.3 Contraindications

TIVICAY is contraindicated in patients with known hypersensitivity to dolutegravir or to any of the excipients.

TIVICAY must not be administered concurrently with medicinal products with narrow therapeutic windows, that are substrates of organic cation transporter 2 (OCT2), including but not limited to dofetilide, pilsicainide or fampridine (see section 4.5 Interactions with other medicines and other forms of interaction).

4.4 Special warnings and precautions for use

Hypersensitivity reactions

Hypersensitivity reactions have been reported with integrase inhibitors, including TIVICAY, and were characterized by rash, constitutional findings, and sometimes, organ dysfunction, including liver injury. Discontinue TIVICAY and other suspect agents immediately if signs or symptoms of hypersensitivity reactions develop (including, but not limited to, severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial oedema, hepatitis, eosinophilia, angioedema). Clinical status including liver aminotransferases should be monitored and appropriate therapy initiated. Delay in stopping treatment with TIVICAY or other suspect agents after the onset of hypersensitivity may result in a life-threatening reaction.

Immune Reconstitution Syndrome

In HIV-infected patients with severe immune deficiency at the time of initiation of anti-retroviral therapy (ART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise and cause serious clinical conditions, or aggravation of symptoms. Typically, such reactions have been observed within the first few weeks or months of initiation of ART. Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections and *Pneumocystis jirovecii* (*P. carinii*) pneumonia. Any inflammatory symptoms must be evaluated without delay and treatment initiated when necessary. Autoimmune disorders (such as Graves' disease, polymyositis and Guillain-Barre syndrome) have also been reported to occur in the setting of immune reconstitution, however, the time to onset is more variable, and can occur many months after initiation of treatment and sometimes can be an atypical presentation.

Liver chemistry elevations consistent with immune reconstitution syndrome were observed in some hepatitis B and/or C co-infected patients at the start of TIVICAY therapy. Monitoring of liver chemistries is recommended in patients with hepatitis B and/or C co-infection. Particular diligence should be applied in initiating or maintaining effective hepatitis B therapy (referring to treatment guidelines) when starting dolutegravir-based therapy in hepatitis B co-infected patients (see section 4.8 Undesirable effects).

Opportunistic infections

Patients receiving TIVICAY or any other antiretroviral therapy may still develop opportunistic infections and other complications of HIV infection. Therefore patients should remain under close clinical observation by physicians experienced in the treatment of these associated HIV diseases.

Drug interactions

Caution should be given to co-administering medications (prescription and non-prescription) that may change the exposure of TIVICAY or medications that may have their exposure changed by TIVICAY (see section 4.3 Contraindications and section 4.5 Interaction with other medicines and other forms of interaction).

The recommended dose of TIVICAY is 50 mg twice daily when co-administered with efavirenz (without boosted protease inhibitors), efavirenz, nevirapine, tipranavir/ritonavir, rifampicin, carbamazepine, phenytoin, phenobarbital, and St. John's wort (see section 4.5 Interaction with other medicines and other forms of interaction).

TIVICAY should not be co-administered with polyvalent cation-containing antacids. TIVICAY is recommended to be administered two hours before or six hours after these agents (see section 4.5 Interaction with other medicines and other forms of interaction).

TIVICAY is recommended to be administered 2 hours before or 6 hours after taking calcium or iron supplements, or alternatively, administered with food (see section 4.5 Interaction with other medicines and other forms of interaction).

TIVICAY increases metformin concentrations. A dose adjustment of metformin should be considered when starting and stopping co-administration of TIVICAY with metformin, to maintain glycaemic control (see section 4.5 Interaction with other medicines and other forms of interaction).

Dual Regimens

Rilpivirine and dolutegravir

The dual regimen of rilpivirine and dolutegravir is only suitable for the treatment of HIV-1 infection in those patients who are virologically suppressed (HIV-1 RNA <50 copies/mL) where there is no known or suspected resistance to either ART component.

Lamivudine and dolutegravir

The dual regimen of lamivudine and dolutegravir is only suitable for the treatment of HIV-1 infection where there is no known or suspected resistance to either ART component.

Paediatric population

The safety and efficacy of TIVICAY has not yet been established in children (< 12 years or weighing less than 40 kg).

Use in the elderly

There are limited data available on the use of TIVICAY in patients aged 65 years and over. However, there is no evidence that elderly patients require a different dose than younger adult patients (see section 5.2 Pharmacokinetic properties – Special populations).

4.5 Interactions with other medicines and other forms of interaction

Effect of other agents on the pharmacokinetics of TIVICAY

Dolutegravir is metabolized by uridine diphosphate glucouronosyl transferase (UGT1)A1 with some contribution from cytochrome P450 (CYP3A). Dolutegravir is also a substrate of UGT1A3, UGT1A9, breast cancer resistance protein (BCRP), and P-glycoprotein (P-gp) *in vitro*. Drugs that induce those enzymes or transporters may decrease dolutegravir plasma concentration and reduce the therapeutic effect of dolutegravir. Co-administration of dolutegravir and other drugs that inhibit these enzymes may increase dolutegravir plasma concentrations.

In vitro, dolutegravir is not a substrate of human organic anion transporting polypeptide (OATP)1B1, OATP1B3, or the renal organic cation transporter (OCT1), therefore drugs that solely modulate these transporter are not expected to affect dolutegravir plasma concentration.

Selected drug interactions are presented in Table 1. Recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious adverse events or loss of efficacy.

Effect of TIVICAY on the pharmacokinetics of other agents

In vitro, dolutegravir inhibited the renal organic cation transporter, OCT2 (IC₅₀ = 1.93 µM), multidrug and toxin extrusion transporter (MATE) 1 (IC₅₀ = 6.34 µM) and MATE2-K (IC₅₀ = 24.8 µM). Given dolutegravir's *in vivo* exposure, it has a low potential to affect the transport of MATE2-K substrates *in vivo*. *In vivo*, dolutegravir inhibits tubular secretion of creatinine by inhibiting OCT2. *In vivo* dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (for example dofetilide, pilsicainide, fampridine or metformin) (see Table 1).

In vitro, dolutegravir inhibited the basolateral renal transporters: OAT1 (IC₅₀ = 2.12 µM) and OAT3 (IC₅₀ = 1.97 µM). However, dolutegravir had no notable effect on the *in vivo* pharmacokinetics of the OAT substrates tenofovir and para aminohippurate, and therefore has low propensity to cause drug interactions via inhibition of OAT transporters.

In vitro, dolutegravir did not inhibit (IC₅₀ >50 µM) the following: CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A, UGT1A1, UGT2B7, P-gp, BCRP, BSEP organic anion transporter polypeptide (OATP)1B1, OATP1B3, OCT1, or multidrug resistance protein (MRP)2 or (MRP)4. *In vitro*, dolutegravir did not induce CYP1A2, CYP2B6, or CYP3A4. Based on these data, dolutegravir is not expected to affect the pharmacokinetics of drugs that are substrates of these enzymes or transporters.

Table 1 Drug Interactions

Concomitant Drug Class: Drug Name	Effect on Concentration of Dolutegravir or Concomitant Drug	Clinical Comment
HIV-1 Antiviral Agents		

Concomitant Drug Class: Drug Name	Effect on Concentration of Dolutegravir or Concomitant Drug	Clinical Comment
Non-nucleoside Reverse Transcriptase Inhibitor: Etravirine (ETR) without boosted protease inhibitors	Dolutegravir ↓ AUC ↓ 71% C _{max} ↓ 52% C _τ ↓ 88% ETR ↔	Etravirine without boosted proteases inhibitors decreased plasma dolutegravir concentration. The recommended dose of dolutegravir is 50 mg twice daily when co-administered with etravirine without boosted protease inhibitors. Dolutegravir should not be used with etravirine without co-administration of atazanavir/ritonavir, darunavir/ritonavir or lopinavir/ritonavir in INI resistant patients.
Protease Inhibitor: Lopinavir/ritonavir + Etravirine	Dolutegravir ↔ AUC ↑ 11% C _{max} ↑ 7% C _τ ↑ 28% LPV ↔ RTV ↔	Lopinavir/ritonavir and etravirine did not change dolutegravir plasma concentration to a clinically relevant extent. No dose adjustment is necessary.
Protease Inhibitor: Darunavir/ritonavir + Etravirine	Dolutegravir ↓ AUC ↓ 25% C _{max} ↓ 12% C _τ ↓ 36% DRV ↔ RTV ↔	Darunavir/ritonavir and etravirine did not change dolutegravir plasma concentration to a clinically relevant extent. No dose adjustment is necessary.
Non-nucleoside Reverse Transcriptase Inhibitor: Efavirenz (EFV)	Dolutegravir ↓ AUC ↓ 57% C _{max} ↓ 39% C _τ ↓ 75% EFV ↔	Efavirenz decreased dolutegravir plasma concentrations. The recommended dose of dolutegravir is 50 mg twice daily when co-administered with efavirenz. Alternative combinations that do not include efavirenz should be used where possible in INI-resistant patients.
Non-nucleoside Reverse Transcriptase Inhibitor: Nevirapine	Dolutegravir ↓	Co-administration with nevirapine has the potential to decrease dolutegravir plasma concentration due to enzyme induction and has not been studied. Effect of nevirapine on dolutegravir exposure is likely similar to or less than that of efavirenz. Alternative combinations that do not include nevirapine should be used where possible in INI-resistant patients.

Concomitant Drug Class: Drug Name	Effect on Concentration of Dolutegravir or Concomitant Drug	Clinical Comment
Protease Inhibitor (PI): Atazanavir (ATV)	Dolutegravir ↑ AUC ↑ 91% C _{max} ↑ 50% C _τ ↑ 180% ATV ↔	Atazanavir increased dolutegravir plasma concentration. No dose adjustment is necessary.
Protease Inhibitor: Atazanavir/ritonavir (ATV/RTV)	Dolutegravir ↑ AUC ↑ 62% C _{max} ↑ 34% C _τ ↑ 121% ATV ↔ RTV ↔	Atazanavir/ritonavir increased dolutegravir plasma concentration. No dose adjustment is necessary.
Protease Inhibitor: Tipranavir/ritonavir (TPV/RTV)	Dolutegravir ↓ AUC ↓ 59% C _{max} ↓ 47% C _τ ↓ 76% TPV ↔ RTV ↔	Tipranavir/ritonavir decreases dolutegravir concentrations. The recommended dose of dolutegravir is 50 mg twice daily when co-administered with tipranavir/ritonavir. Alternative combinations that do not include tipranavir/ritonavir should be used where possible in INI resistant patients.
Protease Inhibitor: Fosamprenavir/ritonavir (FPV/RTV)	Dolutegravir ↓ AUC ↓ 35% C _{max} ↓ 24% C _τ ↓ 49% FPV ↔ RTV ↔	Fosamprenavir/ritonavir decreases dolutegravir concentrations, but based on limited data, did not result in decreased efficacy in Phase III studies. No dose adjustment is necessary in INI-naïve patients. Alternative combinations that do not include fosamprenavir/ritonavir should be used where possible in INI resistant patients.
Protease Inhibitor: Nelfinavir	Dolutegravir ↔	This interaction has not been studied. Although an inhibitor of CYP3A4, based on data from other inhibitors, an increase is not expected. No dose adjustment is necessary.
Protease Inhibitor: Lopinavir/ritonavir (LPV+RTV)	DTG ↔ AUC ↓ 4% C _{max} ↔ C _τ ↓ 6% LPV ↔ RTV ↔	Lopinavir/ritonavir did not change dolutegravir plasma concentration to a clinically relevant extent. No dose adjustment is necessary.

Concomitant Drug Class: Drug Name	Effect on Concentration of Dolutegravir or Concomitant Drug	Clinical Comment
Protease Inhibitor: Darunavir/ritonavir	Dolutegravir ↓ AUC ↓ 22% C _{max} ↓ 11% C _τ ↓ 38%	Darunavir/ritonavir did not change dolutegravir plasma concentration to a clinically relevant extent. No dose adjustment is necessary.
Nucleoside Reverse Transcriptase Inhibitor: Tenofovir	Dolutegravir ↔ AUC ↔ C _{max} ↓ 3% C _τ ↓ 8% Tenofovir ↔ AUC ↑ 12 % C _{max} ↑ 9% C _τ ↑ 19 %	Tenofovir did not change dolutegravir plasma concentration to a clinically relevant extent. No dose adjustment is necessary.
Other Agents		
Dofetilide Pilsicainide	Dofetilide ↑ Pilsicainide ↑	Co-administration of dolutegravir has the potential to increase dofetilide or pilsicainide plasma concentration via inhibition of OCT2 transporter; co-administration has not been studied. Dofetilide or pilsicainide co-administration is contraindicated due to potential life-threatening toxicity caused by high dofetilide or pilsicainide concentration.
Fampridine	Fampridine ↑	Co-administration of dolutegravir has the potential to cause seizures due to increased fampridine plasma concentration via inhibition of OCT2 transporter; co-administration has not been studied. Fampridine co-administration with dolutegravir is contraindicated.
Carbamazepine	Dolutegravir ↓ AUC ↓ 49% C _{max} ↓ 33% C _τ ↓ 73%	Carbamazepine decreased dolutegravir plasma concentration. The recommended dose of dolutegravir is 50 mg twice daily when co-administered with carbamazepine. Alternatives to carbamazepine should be used where possible for INI resistant patients.
Phenytoin	Dolutegravir ↓	Co-administration with these metabolic inducers has the potential to decrease dolutegravir plasma concentration due to

Concomitant Drug Class: Drug Name	Effect on Concentration of Dolutegravir or Concomitant Drug	Clinical Comment
Phenobarbital St. John's wort		enzyme induction and has not been studied. Effect of these metabolic inducers on dolutegravir exposure is likely similar to carbamazepine. The recommended dose of dolutegravir is 50 mg twice daily when co-administered with these metabolic inducers. Alternative combinations that do not include these metabolic inducers should be used where possible in INI-resistant patients.
Oxcarbazepine	Dolutegravir ↓	This interaction has not been studied. Although an inducer of CYP3A4, based on data from other inducers, a clinically significant decrease in dolutegravir is not expected. No dose adjustment is necessary.
Antacids containing polyvalent cations (e.g., Mg, Al)	Dolutegravir ↓ AUC ↓ 74% C _{max} ↓ 72% C24 ↓ 74%	Co-administration of antacids containing polyvalent cations decreased dolutegravir plasma concentration. Dolutegravir is recommended to be administered 2 hours before or 6 hours after taking antacid products containing polyvalent cations.
Calcium supplements	Dolutegravir ↓ AUC ↓ 39% C _{max} ↓ 37% C24 ↓ 39%	Dolutegravir is recommended to be administered 2 hours before or 6 hours after taking products containing calcium, or alternatively, administer with food.
Iron supplements	Dolutegravir ↓ AUC ↓ 54% C _{max} ↓ 57% C24 ↓ 56%	Dolutegravir is recommended to be administered 2 hours before or 6 hours after taking products containing iron, or alternatively, administer with food.
Metformin	Metformin ↑ When co-administered with dolutegravir 50mg QD: Metformin AUC ↑ 79% C _{max} ↑ 66% When co-administered with dolutegravir 50mg BID:	Co-administration of dolutegravir increased metformin plasma concentration. A dose adjustment of metformin should be considered when starting and stopping co-administration of dolutegravir with metformin, to maintain glycaemic control.

Concomitant Drug Class: Drug Name	Effect on Concentration of Dolutegravir or Concomitant Drug	Clinical Comment
	Metformin AUC ↑ 145 % C _{max} ↑ 111%	
Rifampicin	Dolutegravir ↓ AUC ↓ 54% C _{max} ↓ 43% C _τ ↓ 72%	Rifampicin decreased dolutegravir plasma concentration. The recommended dose of dolutegravir is 50 mg twice daily when co-administered with rifampicin. Alternatives to rifampicin should be used where possible for INI resistant patients.
Oral contraceptives (Ethinyl estradiol (EE) and Norelgestromin (NGMN))	Effect of Dolutegravir: EE ↔ AUC ↑ 3% C _{max} ↓ 1% C _τ ↑ 2% Effect of Dolutegravir: NGMN ↔ AUC ↓ 2% C _{max} ↓ 11% C _τ ↓ 7%	Dolutegravir did not change ethinyl estradiol and norelgestromin plasma concentrations to a clinically relevant extent. No dose adjustment of oral contraceptives is necessary when co-administered with dolutegravir.
Methadone	Effect of Dolutegravir: Methadone ↔ AUC ↓ 2% C _{max} ↔ 0% C _τ ↓ 1%	Dolutegravir did not change methadone plasma concentrations to a clinically relevant extent. No dose adjustment of methadone is necessary when co-administered with dolutegravir.
Daclatasvir	Dolutegravir ↔ AUC ↑ 33% C _{max} ↑ 29% C _τ ↑ 45% Daclatasvir ↔	Daclatasvir did not change dolutegravir plasma concentration to a clinically relevant extent. Dolutegravir did not change daclatasvir plasma concentration. No dose adjustment is necessary.

Abbreviations: ↑ = Increase; ↓ = decrease; ↔ = no significant change; AUC=area under the concentration versus time curve; C_{max}=maximum observed concentration, C_τ=concentration at the end of dosing interval

4.6 Fertility, pregnancy and lactation

Pregnancy (Category B1)

TIVICAY can be used during pregnancy if the expected benefit justifies the potential risk to the foetus.

Two large birth outcome surveillance studies in Botswana (Tsepamo) and Eswatini, which together include over 14,000 women taking dolutegravir-containing regimens at conception, show no increased risk of neural tube defects with dolutegravir exposure at conception. Data from the Tsepamo study show no significant difference in neural tube defect prevalence in infants whose mothers were exposed to dolutegravir at conception compared to those taking non-dolutegravir containing antiretroviral regimens at conception, or compared to women without HIV. Data from the Eswatini study show similar rates of neural tube defects between infants whose mothers were on dolutegravir at conception compared with women without HIV. These studies refute an initial finding from a preliminary analysis of the Tsepamo study which suggested a possible increased risk. Data analysed to date from these studies and other sources do not support a causal relationship between dolutegravir and neural tube defects. In the Tsepamo study, which includes over 9,460 exposures to dolutegravir at conception, the prevalence of neural tube defects in infants delivered to women taking dolutegravir at conception was 0.11%. This was the same as the prevalence for non-dolutegravir containing regimens (0.11%), and did not differ significantly from the prevalence in infants delivered to women without HIV (0.07%).

In the Eswatini study, which includes over 4,800 exposures to dolutegravir at conception, the prevalence of neural tube defects in infants delivered to women taking dolutegravir at conception was 0.08%, which was the same as in infants delivered to women without HIV (0.08%).

The incidence of neural tube defects in the general population ranges from 0.5-1 case per 1,000 live births. The prevalence of neural tube defects in infants born to women taking dolutegravir at conception in these two studies did not differ significantly from the background rate in women without HIV, or other ART exposure groups.

Data analysed from the Antiretroviral Pregnancy Registry (APR) in over 870 exposures to dolutegravir in the first trimester of pregnancy do not indicate an increased risk of major birth defects compared to the background rate (see *Clinical Studies*). More than 1,000 outcomes from second and third trimester exposure in pregnant women indicate no evidence of increased risk of adverse birth outcomes.

In animal reproductive toxicity studies no adverse development outcomes, including neural tube defects, were identified.

Oral administration of dolutegravir to pregnant rats at doses up to 1000 mg/kg daily from days 6 to 17 of gestation did not elicit maternal toxicity, developmental toxicity or teratogenicity (27 times the 50 mg human clinical exposure based on AUC at the maximum recommended dose of 50 mg BID).

Oral administration of dolutegravir to pregnant rabbits at doses up to 1000 mg/kg daily from days 6 to 18 of gestation was associated with marked maternal toxicity, but did not elicit developmental toxicity or teratogenicity in the offspring (0.4 times the clinical exposure based on AUC).

Dolutegravir readily crosses the placenta in humans. In pregnant women with HIV, the median (range) foetal umbilical cord concentrations of dolutegravir were 12.8 (1.21 to 1.28) fold greater compared with maternal peripheral plasma concentrations.

There is insufficient information on the effects of dolutegravir on neonates.

Breast-feeding

Health experts recommend that where possible HIV infected women do not breast feed their infants in order to avoid transmission of HIV. In settings where formula feeding is not feasible, local official lactation and treatment guidelines should be followed when considering breast feeding during antiretroviral therapy.

Dolutegravir is excreted in human milk in small amounts. In an open-label randomised study in which HIV-infected treatment-naïve pregnant women were administered a dolutegravir based regimen until two weeks post-partum, the median (range) dolutegravir breast milk to maternal plasma ratio was 0.033 (0.021 to 0.050).

Fertility

There are no data on the effects of TIVICAY on human male or female fertility. TIVICAY did not affect male or female mating or fertility in rats at doses up to 1000 mg/kg/day associated with an exposure level 24 times the clinical exposure based on AUC at the maximum recommended dose of 50 mg BID.

4.7 Effects on ability to drive and use machines

There have been no studies to investigate the effect of TIVICAY on driving performance or the ability to operate machinery.

The clinical status of the patient and the adverse event profile of TIVICAY should be borne in mind when considering the patient's ability to drive or operate machinery.

4.8 Undesirable effects

Summary of the safety profile

Clinical trial data

Antiretroviral Naïve Patients

The safety assessment of TIVICAY in HIV-1-infected treatment-naïve patients is based on the analyses of 96-week data from 2, international, multicentre, double-blind trials, SPRING-2 (ING113086) and SINGLE (ING114467) and 48-week data from the international, multicentre, open-label FLAMINGO (ING114915) trial.

In SPRING 2, 822 patients were randomised and received at least 1 dose of either TIVICAY 50 mg once daily or raltegravir 400 mg twice daily, both in combination with fixed-dose dual nucleoside reverse transcriptase inhibitor (NRTI) treatment (either abacavir sulfate/lamivudine or emtricitabine/tenofovir). Through 96 weeks the rates of discontinuation due to adverse events were 2% in patients receiving TIVICAY 50 mg once daily + either abacavir sulfate/lamivudine or emtricitabine/tenofovir and 1% in patients receiving raltegravir 400 mg twice daily + either abacavir sulfate/lamivudine or emtricitabine/tenofovir.

In SINGLE, 833 patients were randomised and received at least 1 dose of either TIVICAY 50 mg with fixed-dose abacavir sulfate/lamivudine once daily or fixed-dose efavirenz/emtricitabine/tenofovir once daily. Through 96 weeks, the rates of discontinuation due to adverse events were 3% in patients receiving TIVICAY 50 mg once daily + abacavir

sulfate/lamivudine and 12% in patients receiving efavirenz/emtricitabine/tenofovir once daily.

Treatment-emergent adverse reactions (adverse events assessed as causally related by the investigator) of moderate to severe intensity with a $\geq 2\%$ frequency in either treatment arm in SPRING-2 and SINGLE trials are provided in Table 2. Side-by-side tabulation is to simplify presentation; direct comparisons across trials should not be made due to differing trial designs.

Tabulated summary of adverse reactions

Table 2 Treatment-Emergent Adverse Reactions of at Least Moderate Intensity (Grades 2 to 4) and $\geq 2\%$ Frequency in Treatment-Naive Patients in SPRING-2 and SINGLE Trials (Week 96 Analysis)

Body System/ Preferred Term	SPRING-2		SINGLE	
	TIVICAY 50 mg Once Daily+ 2 NRTIs (N = 411)	Raltegravir 400 mg Twice Daily + 2 NRTIs (N = 411)	TIVICAY 50 mg + KIVEXA Once Daily (N = 414)	EFV/TDF/FTC Once Daily (N = 419)
Psychiatric				
Insomnia	1 (<1%)	1 (<1%)	14 (3%)	10 (2%)
Depression	1 (<1%)	1 (<1%)	5 (1%)	9 (2%)
Abnormal dreams	2 (<1%)	1 (<1%)	3 (<1%)	8 (2%)
Nervous System				
Dizziness	1 (<1%)	1 (<1%)	2 (<1%)	21 (5%)
Headache	3 (<1%)	4 (<1%)	8 (2%)	9 (2%)
Gastrointestinal				
Nausea	6 (1%)	5 (1%)	3 (<1%)	12 (3%)
Diarrhea	3 (<1%)	2 (<1%)	4 (<1%)	7 (2%)
General Disorders				
Fatigue	2 (<1%)	1 (<1%)	7 (2%)	7 (2%)
Skin and Subcutaneous Tissue				
Rash ^a	0	2 (<1%)	2 (<1%)	25 (6%)
Ear and Labyrinth				
Vertigo	0	1 (<1%)	0	7 (2%)

^a Includes pooled terms: rash, rash generalized, rash macular, rash maculo-papular, rash pruritic, and drug eruption.

Laboratory abnormalities with a worsening grade from baseline in $\geq 2\%$ (for Grades 3 to 4 combined) of patients are presented in Table 3. Side-by-side tabulation is to simplify presentation; direct comparisons across trials should not be made due to differing trial designs.

Table 3 Laboratory Abnormalities ($\geq 2\%$ for Grades 3 to 4 Combined) in Treatment-Naïve Patients in SPRING-2 and SINGLE Trials (Week 96 Analysis)

Laboratory Parameter Preferred Term (Unit)	SPRING-2		SINGLE	
	TIVICAY 50 mg Once Daily + 2 NRTIs (N = 411)	Raltegravir 400 mg Twice Daily + 2 NRTIs (N = 411)	TIVICAY 50 mg + KIVEXA Once Daily (N = 414)	EFV/TDF/FTC Once Daily (N = 419)
ALT (IU/L)				
Grade 3 (5.1-10.0 x ULN)	5 (1%)	6 (1%)	1 (<1%)	1 (<1%)
Grade 4 (>10.0 x ULN)	5 (2%)	2 (<1%)	1 (<1%)	1 (<1%)
AST (IU/L)				
Grade 3 (5.1-10.0 x ULN)	8 (2%)	8 (2%)	1 (<1%)	9 (2%)
Grade 4 (>10.0 x ULN)	6 (1%)	2 (<1%)	0	2 (<1%)
Creatine kinase (IU/L)				
Grade 3 (10.0-19.9 x ULN)	9 (2%)	10 (2%)	11 (3%)	11 (3%)
Grade 4 (≥ 20.0 x ULN)	18 (4%)	8 (2%)	10 (2%)	17 (4%)
Lipase (U/L)				
Grade 3 (3.1-5.0 x ULN)	6 (1%)	13 (3%)	10 (2%)	11 (3%)
Grade 4 (>5.0 x ULN)	3 (<1%)	6 (1%)	6 (1%)	2 (<1%)
Total neutrophils ($10^3/\mu\text{L}$)				
Grade 3 (0.50-0.749 x 10^9)	5 (1%)	3 (<1%)	8 (2%)	7 (2%)
Grade 4 (<0.50 x 10^9)	3 (<1%)	5 (<1%)	2 (<1%)	7 (2%)

ULN = Upper limit of normal.

In a multicentre, open-label trial (FLAMINGO), 243 patients received TIVICAY 50 mg once daily versus 242 patients who received darunavir 800 mg/ritonavir 100 mg once daily, both in combination with investigator-selected NRTI background regimen (either KIVEXA or TDF/FTC). There were 484 patients included in the efficacy and safety analyses. Through 48 weeks, the rates of adverse events leading to discontinuation were 2% in patients receiving TIVICAY and 4% in patients receiving darunavir/ritonavir. The ADRs observed in FLAMINGO were generally consistent with those seen in SPRING-2 and SINGLE.

Laboratory abnormalities observed in the FLAMINGO trial were generally consistent with observations in SPRING-2 and SINGLE.

Antiretroviral experienced (and integrase inhibitor naïve) patients

In an international, multicentre, double-blind trial SAILING (ING111762), 719 HIV-1-infected, antiretroviral treatment-experienced adults were randomised and received either TIVICAY 50 mg once daily or raltegravir 400 mg twice daily with investigator-selected background regimen consisting of up to 2 agents, including at least one fully active agent. At 48 weeks, the rates of discontinuation due to adverse events were 2% (/7/357) in patients

receiving TIVICAY 50 mg once daily + background regimen and 4% (13/362) in patients receiving raltegravir 400 mg twice daily + background regimen.

The only treatment-emergent adverse reaction (adverse event assessed as causally related by the investigators) of moderate to severe intensity with a $\geq 2\%$ frequency in either treatment group was diarrhea, 2% (6/357) in patients receiving TIVICAY 50 mg once daily + background regimen and 1% (5/362) in patients receiving raltegravir 400 mg twice daily + background regimen.

Laboratory abnormalities observed in SAILING were generally similar compared with observations seen in the treatment-naïve (SPRING-2 and SINGLE) trials.

Integrase inhibitor resistant patients

In a multicentre, open-label, single-arm trial VIKING-3 (ING112574), 183 HIV-1-infected, antiretroviral treatment-experienced adults with virological failure and current or historical evidence of raltegravir and/or elvitegravir resistance received TIVICAY 50 mg twice daily with the current failing background regimen for 7 days and with optimized background therapy from Day 8. The rate of discontinuation due to adverse events was 4% of patients at Week 48.

Treatment-emergent ADRs in VIKING-3 were generally similar compared with observations with the 50-mg once-daily dose in adult Phase 3 trials.

The most common treatment-emergent laboratory abnormalities ($>5\%$ for Grades 2 to 4 combined) observed in VIKING-3 at Week 48 were elevated ALT (9%), AST (8%), cholesterol (10%), creatine kinase (6%), hyperglycemia (14%), and lipase (10%). Two percent (4/183) of patients had a Grade 3 to 4, treatment-emergent hematology laboratory abnormality, with neutropenia (2% [3/183]) being the most frequently reported.

Changes in clinical laboratory values

Increases in serum creatinine occurred within the first week of treatment with dolutegravir and remained stable through 48 weeks. In treatment-naïve patients a mean change from baseline of $0.9.96 \mu\text{mol/L}$ (range: $-53 \mu\text{mol/L}$ to $54.8 \mu\text{mol/L}$) was observed after 48 weeks of treatment. Creatinine increases were comparable by background NRTIs, and were similar in treatment-experienced patients. These changes are not considered to be clinically relevant since they do not reflect a change in glomerular filtration rate (GFR) (see section 5.2 Pharmacokinetic properties – Renal impairment).

Small increases in total bilirubin (without clinical jaundice) were observed on dolutegravir and raltegravir (but not efavirenz) arms in the clinical trials. These changes are not considered clinically relevant as they likely reflect competition between dolutegravir and unconjugated bilirubin for a common clearance pathway, UGT1A1.

Asymptomatic creatine phosphokinase (CPK) elevations mainly in association with exercise have also been reported with dolutegravir therapy.

Less common adverse reactions observed in treatment-naïve and treatment-experienced trials

The following adverse reactions occurred in <2% of treatment-naïve or treatment-experienced patients in any one trial receiving TIVICAY in a combination regimen. These events have been included because of their seriousness and assessment of potential causal relationship.

Gastrointestinal disorders: Abdominal pain, abdominal discomfort, flatulence, upper abdominal pain, vomiting.

General disorders: Fatigue.

Hepatobiliary disorders: Hepatitis.

Immune system disorders: Hypersensitivity, immune reconstitution syndrome.

Psychiatric disorders: Suicidal ideation, attempt, behavior, or completion. These events were observed primarily in subjects with a pre-existing history of depression or other psychiatric illness.

Skin and subcutaneous tissue disorders: Pruritus.

Paediatric population

Based on limited available data in children and adolescents (12 to less than 18 years of age), there were no additional types of adverse reactions beyond those observed in the adult population.

Other special populations

Co-infection with Hepatitis B or C

In Phase III studies, patients with hepatitis B and/or C co-infection were permitted to enrol provided that baseline liver chemistry tests did not exceed 5 times the upper limit of normal (ULN). Overall, the safety profile in patients co-infected with hepatitis B and/or C was similar to that observed in patients without hepatitis B or C co-infection, although the rates of AST and ALT abnormalities were higher in the subgroup with hepatitis B and/or C co-infection for all treatment groups. Liver chemistry elevations consistent with immune reconstitution syndrome were observed in some patients with hepatitis B and/or C co-infection at the start of TIVICAY therapy, particularly in those whose anti-hepatitis B therapy was withdrawn (see section 4.4 Special warnings and precautions for use).

Post marketing data

Blood and lymphatic system disorders	Very rare	Sideroblastic anaemia*
Hepatobiliary disorders	Rare	Acute hepatic failure**
Musculoskeletal and connective tissue disorders	Uncommon Uncommon	Arthralgia, Myalgia
Psychiatric disorders	Common	Anxiety

Investigations	Common	Weight increased
----------------	--------	------------------

*Reversible sideroblastic anaemia has been reported with dolutegravir-containing regimens. The contribution of dolutegravir in these cases is unclear.

**Acute hepatic failure has been reported in a dolutegravir-containing regimen. The contribution of dolutegravir in these cases is unclear.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via: <https://pophealth.my.site.com/carmreportnz/s/>

4.9 Overdose

Symptoms and signs

There is currently limited experience with overdosage in TIVICAY.

Limited experience of single higher doses (up to 250 mg in healthy patients) revealed no specific symptoms or signs, apart from those listed as adverse reactions.

Treatment

Further management should be as clinically indicated or as recommended by the national poisons centre, where available.

There is no specific treatment for an overdose of TIVICAY. If overdose occurs, the patient should be treated supportively with appropriate monitoring as necessary. As TIVICAY is highly bound to plasma proteins, it is unlikely that it will be significantly removed by dialysis. Further management should be as clinically indicated or as recommended by the national poisons centre, where available.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).


5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antiviral for systemic use, Other Antivirals, ATC code: J05AJ03.

The chemical (IUPAC) name for dolutegravir sodium is Sodium (4R,12aS)-9-[(2,4-difluorophenyl)methyl]carbamoyl]-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazin-7-olate.

The structural formula is:



Molecular formula: C₂₀H₁₈F₂N₃NaO₅

Molecular weight of 441.36 g/mol.

CAS Registry Number: 1051375-19-9

Mechanism of action

Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral Deoxyribonucleic acid (DNA) integration which is essential for the HIV replication cycle. Strand transfer biochemical assays using purified HIV 1 integrase and pre-processed substrate DNA resulted in IC₅₀ values of 2.7 nM and 12.6 nM. In vitro, dolutegravir dissociates slowly from the active site of the wild type integrase-DNA complex (t_{1/2} 71 hours).

Pharmacodynamic effects

In a randomised, dose-ranging trial, HIV-1-infected patients treated with dolutegravir monotherapy (ING111521) demonstrated rapid and dose-dependent antiviral activity, with mean declines from baseline to day 11 in HIV-1 RNA of 1.5, 2.0, and 2.5 log₁₀ for dolutegravir 2 mg, 10 mg, and 50 mg once daily, respectively. This antiviral response was maintained for 3 to 4 days after the last dose in the 50 mg group.

Antiviral activity in cell culture

Dolutegravir exhibited antiviral activity against laboratory strains of wild type HIV-1 in peripheral blood mononuclear cells (PBMC) and MT4 cells with mean EC₅₀s of 0.5 nM to 2.1 nM.

In a viral integrase susceptibility assay using the integrase coding region from 13 clinically diverse clade B isolates, dolutegravir demonstrated antiviral potency similar to laboratory strains, with a mean EC₅₀ of 0.52 nM. When tested in PBMC assays against a panel consisting of 24 HIV-1 clinical isolates [group M (clade A, B, C, D, E, F and G) and group O] and 3 HIV-2 clinical isolates, the geometric mean EC₅₀ was 0.20 nM and EC₅₀ values ranged from 0.02 to 2.14 nM for HIV-1, while the geometric mean EC₅₀ was 0.18 nM and EC₅₀ values ranged from 0.09 to 0.61 nM for HIV-2 isolates.

Antiviral activity in combination with other antiviral agents

The antiviral activity of dolutegravir in vitro was not antagonistic with the integrase inhibitor (INI) raltegravir; the non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz or nevirapine; the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir or stavudine; the protease inhibitors (PIs) amprenavir or lopinavir; the CCR5 co-receptor antagonist maraviroc; or the fusion inhibitor enfuvirtide. Dolutegravir antiviral activity was not antagonistic when combined with the HBV reverse transcriptase inhibitor adefovir, or inhibited by the antiviral ribavirin.

Resistance in vitro

Dolutegravir-resistant viruses were selected in studies of potential resistance using different wild type strains and clades of HIV-1. Amino acid substitutions that emerged during passaging included E92Q, G193E, G118R, S153F or Y, and R263K, and were associated with decreased susceptibility to dolutegravir of up to 11-fold.

In resistance development studies starting with the single raltegravir resistance mutants Q148H, Q148K or Q148R, additional mutations detected during passage with dolutegravir included E138K/Q148K, E138K/Q148R, Q140S/Q148R and G140S/Q148R, which all exhibited greater than ten-fold reductions in sensitivity to dolutegravir.

Anti-HIV activity against resistant strains: Reverse Transcriptase Inhibitor- and Protease Inhibitor-Resistant Strains: Dolutegravir demonstrated equivalent potency against 2 non-nucleoside (NN)-RTI-resistant, 3 nucleoside (N)-RTI-resistant, and 2 PI-resistant HIV-1 mutant clones (1 triple and 1 sextuple) compared to the wildtype strain.

Cross resistance: integrase inhibitor-resistant HIV-1 strains: Sixty integrase inhibitor-resistant mutant HIV-1 viruses (28 with single substitutions and 32 with 2 or more substitutions) were produced from wild-type virus NL-432 using site-directed mutagenesis. Dolutegravir showed anti-HIV activity (susceptibility) with FC <5 against 27 of 28 integrase inhibitor-resistant mutant viruses with single substitutions including T66A/I/K, E92Q/V, Y143C/H/R, Q148H/K/R, and N155H. A G118R substitution conferred a 10 fold reduction in dolutegravir susceptibility but has not been observed during dolutegravir clinical studies. The single INSTI resistance substitutions T66K, I151L, and S153Y conferred a >2-fold decrease in dolutegravir susceptibility (range: 2.3-fold to 3.6-fold from reference). Combinations of multiple substitutions T66K/L74M, E92Q/N155H, G140C/Q148R, G140S/Q148H, R or K, Q148R/N155H, T97A/G140S/Q148, and substitutions at E138/G140/Q148 showed a >2-fold decrease in dolutegravir susceptibility (range: 2.5-fold to 21-fold from reference).

Cross resistance: integrase inhibitor-resistant HIV-2 strains: Site directed mutant HIV-2 viruses were constructed based on patients infected with HIV-2 and treated with raltegravir who showed virologic failure. HIV-2 mutants with combinations of substitutions A153G/N155H/S163G and E92Q/T97A/N155H/S163D were associated with four-fold reductions in dolutegravir susceptibility, while susceptibility of viruses with E92Q/N155H and G140S/Q148R substitutions were decreased 8.5 and 17 fold, respectively.

Clinical isolates from raltegravir treatment virologic failure patients: Thirty clinical isolate samples with genotypic and phenotypic resistance to raltegravir (median FC >81) were examined for susceptibility to dolutegravir (median FC 1.5) using the Monogram Biosciences PhenoSense assay. The median FC to dolutegravir for isolates containing changes at G140S + Q148H was 3.75; G140S + Q148R was 13.3; T97A + Y143R was 1.05 and N155H was 1.37.

Seven hundred and five raltegravir resistant isolates from raltegravir experienced patients were analysed for susceptibility to dolutegravir using the Monogram Biosciences PhenoSense assay. Dolutegravir has a less than or equal to 10 FC against 93.9% of the 705 clinical isolates, of note 16 (9%) of the 184 isolates with Q148 +1 INSTI-resistance

substitution and 25 (27%) of the 92 clinical isolates with Q148 + ≥ 2 INSTI-resistance substitutions had greater than 10 fold change.

Resistance in vivo: integrase inhibitor naïve patients

No INI-resistant mutations or treatment emergent resistance to the NRTI backbone therapy were isolated with dolutegravir 50 mg once daily in treatment-naïve studies (SPRING-1, SPRING-2, SINGLE, FLAMINGO and GEMINI studies). In the SAILING study for treatment experienced (and integrase naïve) patients (n=354 in the dolutegravir arm), treatment emergent integrase substitutions were observed at Week 48 in 4 of 17 patients receiving dolutegravir with virologic failure. Of these four, 2 patients had a unique R263K integrase substitution, with a maximum FC of 1.93, 1 patient had a polymorphic V151V/I integrase substitution, with maximum FC of 0.92, and 1 patient had pre-existing integrase mutations and is assumed to have been integrase experienced or infected with integrase resistant virus by transmission (see section 5.1 Pharmacodynamic properties - Clinical efficacy and safety data).

Resistance in vivo: integrase inhibitor resistant patients

The VIKING-3 study examined dolutegravir (plus optimized background therapy) in patients with pre-existing INI resistance. Thirty six patients (36/183) experienced protocol defined virologic failure through to Week 24. Of these, 32 had paired baseline and PDVF resistance data for analysis and 17/32 (53%) had treatment emergent mutations. Treatment-emergent mutations or mixtures of mutations observed were L74L/M (n=1), E92Q (n=2), T97A (n=9), E138K/A/T (n=8), G140S (n=2), Y143H (n=1), S147G (n=1), Q148H/K/R (n=4), N155H (n=1) and E157E/Q (n=1). Fourteen of the 17 patients with virus exhibiting treatment-emergent mutations harboured Q148 pathway virus present at baseline or historically. Five further patients experienced PDVF between weeks 24 and 48, and 2 of these 5 had treatment emergent mutations. Treatment-emergent mutations or mixtures of mutations observed were L74I (n=1), N155H (n=2).

The VIKING-4 study examined dolutegravir (plus optimized background therapy) in patients with primary genotypic resistance to INIs at Screening in 30 patients. Treatment-emergent mutations observed were consistent with those observed in the VIKING-3 study.

Resistance in vivo: virologically suppressed subjects

SWORD-1 and SWORD-2 are identical studies that examined stable suppressed subjects receiving 2 NRTIs plus either an INI, an NNRTI, or a PI, that switched to dolutegravir plus rilpivirine (n=513) or remained on their current antiviral regimen (n=511). The number of subjects who met the protocol-defined confirmed virologic withdrawal (CVW) criteria was low across the pooled SWORD-1 and SWORD-2 studies. Two subjects from each treatment arm met CVW criteria at any time through Week 48. NNRTI resistance associated substitution K101K/E mixture with no decreased susceptibility to rilpivirine (FC=0.8) was observed in one subject with identified adherence issues that received dolutegravir plus rilpivirine. No integrase resistance was observed. This patient's viral load was 1,059,771 copies/mL at the suspected virologic withdrawal visit, and on resumption of dolutegravir plus rilpivirine the viral load decreased to 1,018 copies/mL at the confirmatory visit and was <50 copies/mL at the withdrawal visit. No resistance-associated substitutions were observed for the other three subjects meeting CVW criteria.

In the pooled analyses from Week 48 through Week 148, nine additional subjects receiving dolutegravir plus rilpivirine met CVW criteria at any time. Of the eight who had resistance testing results available, six (described below) had postbaseline results or resistance associated substitutions (NNRTI and/or INI).

- Subjects receiving dolutegravir plus rilpivirine from study start who met CVW criteria: At Week 88, one subject had the NNRTI-resistance-associated substitution mixture E138E/A with no decreased susceptibility to rilpivirine (FC = 1.6), and one subject had K103N with rilpivirine FC = 5.2. Neither subject had INSTI resistance-associated substitutions or decreased susceptibility to dolutegravir. At Week 100, one subject with baseline NNRTI-resistance-associated substitutions K101E, E138A had M230M/L in addition to K101E and E138A with rilpivirine FC = 31. Integrase resistance testing failed at virologic failure. At Week 112, one subject had M230M/L mixture with rilpivirine FC = 2, and INSTI polymorphic substitutions E157Q, G193E, T97T/A at baseline and E157Q, G193E at virologic failure with no decreased susceptibility to dolutegravir (FC = 1.5).
- Subjects receiving dolutegravir plus rilpivirine from Week 52 who met CVW criteria: At Week 64, one subject had integrase substitutions N155H, G163G/R at baseline and only polymorphic integrase V151I/V mixture at virologic failure, and no NNRTI resistance. Integrase phenotype assay failed, and HIV-1 RNA was less than 50 copies per mL at withdrawal visit. At Week 136, one subject had NNRTI-resistance-associated substitutions E138A and L100L/I with rilpivirine FC = 4.1 and integrase resistance testing failed at virologic failure.

Effects on electrocardiogram

In a randomised, placebo-controlled, cross-over trial, 42 healthy patients received single dose oral administrations of placebo, dolutegravir 250 mg suspension (exposures approximately 3-fold of the 50 mg once-daily dose at steady state), and moxifloxacin (400 mg, active control) in random sequence. Dolutegravir did not prolong the QTc interval for 24 hours post dose. After baseline and placebo adjustment, the maximum mean QTc change based on Fridericia correction method (QTcF) was 1.99 msec (1-sided 95% upper CI: 4.53 msec).

Effects on renal function

The effect of dolutegravir on serum creatinine clearance (CrCl), glomerular filtration rate (GFR) using iothexol as the probe and effective renal plasma flow (ERPF) using para-aminohippurate (PAH) as the probe was evaluated in an open-label, randomised, 3 arm, parallel, placebo-controlled study in 37 healthy patients, who were administered dolutegravir 50 mg once daily (n=12), 50 mg twice daily (n=13) or placebo once daily (n=12) for 14 days. A modest decrease in CrCl was observed with dolutegravir within the first week of treatment, consistent with that seen in clinical studies. Dolutegravir at both doses had no significant effect on GFR or ERPF. These data support in vitro studies which suggest that the small increases in creatinine observed in clinical studies are due to the nonpathologic inhibition of OCT2 in the proximal renal tubules, which mediates the tubular secretion of creatinine.

Clinical efficacy and safety data

Antiretroviral naïve patients

The efficacy of TIVICAY in HIV-infected, therapy naive patients is based on data from two randomised, international, double-blind, active-controlled trials, 96 week data from SPRING-2 (ING113086) and SINGLE (ING114467). This is supported by 96 week data from an open-label and active-controlled study FLAMINGO (ING114915) and additional data from the open-label phase of SINGLE to 144 weeks. The efficacy of TIVICAY in combination with lamivudine in adults is supported by 144-week data from two identical 148-week, randomised, multicentre, double-blind, non-inferiority studies GEMINI-1 (204861) and GEMINI-2 (205543).

In SPRING-2, 822 adults were randomised and received at least one dose of either TIVICAY 50 mg once daily or raltegravir 400 mg twice daily, both administered with fixed-dose dual NRTI therapy (either ABC/3TC or TDF/FTC). At baseline, median patient age was 36 years, 14% were female, 15% non-white, and 12% had hepatitis B and/or C co-infection and 2% were CDC Class C; these characteristics were similar between treatment groups.

In SINGLE, 833 patients were randomised and received at least one dose of either TIVICAY 50 mg once daily with fixed-dose abacavir-lamivudine (DTG + ABC/3TC) or fixed-dose efavirenz-tenofovir-emtricitabine (EFV/TDF/FTC). At baseline, median patient age was 35 years, 16% were female, 32% non-white, 7% had hepatitis C co-infection and 4% were CDC Class C, these characteristics were similar between treatment groups.

The primary endpoint and other week 48 outcomes (including outcomes by key baseline covariates) for SPRING-2 and SINGLE are shown in Table 4.

Table 4 Virologic Outcomes of Randomised Treatment of SPRING-2 and SINGLE at 48 Weeks (Snapshot algorithm)

	SPRING-2		SINGLE	
	TIVICAY 50 mg Once Daily + 2 NRTI N=411	RAL 400 mg Twice Daily + 2 NRTI N=411	TIVICAY 50 mg + ABC/3TC Once Daily N=414	EFV/TDF/FTC Once Daily N=419
HIV-1 RNA <50 copies/mL	88%	85%	88%	81%
Treatment Difference*	2.5% (95% CI: -2.2%, 7.1%)		7.4% (95% CI: 2.5%, 12.3%) P=0.003	
Virologic non response†	5%	8%	5%	6%
No virologic data at Week 48 window	7%	7%	7%	13%
Reasons				
Discontinued study/study drug due to adverse event or death‡	2%	1%	2%	10%
Discontinued study/study drug for other reasons§	5%	6%	5%	3%
Missing data during window but on study	0%	0	0	<1%
HIV-1 RNA <50 copies/mL by baseline covariates				
Baseline Plasma Viral Load (copies/mL)	n / N (%)	n / N (%)	n / N (%)	n / N (%)
≤100,000	267 / 297 (90%)	264 / 295 (89%)	253 / 280 (90%)	238 / 288 (83%)
>100,000	94 / 114 (82%)	87 / 116 (75%)	111 / 134 (83%)	100 / 131 (76%)

	SPRING-2		SINGLE	
	TIVICAY 50 mg Once Daily + 2 NRTI N=411	RAL 400 mg Twice Daily + 2 NRTI N=411	TIVICAY 50 mg + ABC/3TC Once Daily N=414	EFV/TDF/FTC Once Daily N=419
Baseline CD4+ (cells/ mm³)				
<200	43 / 55 (78%)	34 / 50 (68%)	45 / 57 (79%)	48 / 62 (77%)
200 to <350	128 / 144 (89%)	118 / 139 (85%)	143 / 163 (88%)	126 / 159 (79%)
≥350	190 / 212 (90%)	199 / 222 (90%)	176 / 194 (91%)	164 / 198 (83%)
NRTI backbone				
ABC/3TC	145 / 169 (86%)	142 / 164 (87%)	N/A	N/A
TDF/FTC	216 / 242 (89%)	209 / 247 (85%)	N/A	N/A
Gender				
Male	308 / 348 (89%)	305 / 355 (86%)	307 / 347 (88%)	291 / 356 (82%)
Female	53 / 63 (84%)	46 / 56 (82%)	57 / 67 (85%)	47 / 63 (75%)
Race				
White	306 / 346 (88%)	301 / 352 (86%)	255 / 284 (90%)	238 / 285 (84%)
African-America/African Heritage/Other	55 / 65 (85%)	50 / 59 (85%)	109 / 130 (84%)	99 / 133 (74%)
Age (years)				
<50	324 / 370 (88%)	312 / 365 (85%)	319 / 361 (88%)	302 / 375 (81%)
≥50	37 / 41 (90%)	39 / 46 (85%)	45 / 53 (85%)	36 / 44 (82%)
<p>* Adjusted for baseline stratification factors.</p> <p>† Includes patients who changed BR to new class or changed BR not permitted per protocol or due to lack of efficacy prior to Week 48 (for SPRING-2 only), patients who discontinued prior to Week 48 for lack or loss of efficacy and patients who are ≥50 copies in the 48 week window.</p> <p>‡ Includes patients who discontinued due to an adverse event or death at any time point from Day 1 through the Week 48 window if this resulted in no virologic data on treatment during the Week 48 window.</p> <p>§ Includes reasons such as withdrew consent, loss to follow-up, moved, protocol deviation.</p> <p>Notes: ABC/3TC = abacavir 600 mg, lamivudine 300 mg in the form of Kivexa fixed dose combination (FDC)</p> <p>EFV/TDF/FTC = efavirenz 600 mg, tenofovir 300 mg, emtricitabine 200 mg FDC.</p> <p>N = Number of patients in each treatment group</p>				

In the SPRING-2 study through 96 weeks, virologic suppression (HIV-1 RNA <50 copies/mL) in the TIVICAY group (81%) was non-inferior to the raltegravir group (76%). The median change in CD4+ T cell count from baseline were 230 cells/mm³ in the group receiving TIVICAY and the raltegravir group at 48 weeks and 276 cells/mm³ in the group receiving TIVICAY compared to 264 cells/mm³ the raltegravir group at 96 weeks.

In the SINGLE study at Week 48, virologic suppression (HIV-1 RNA <50 copies/mL) in the TIVICAY + ABC/3TC arm was 88%, which was superior to the EFV/TDF/FTC arm (81%), based on the primary analysis (p=0.003). At 96 weeks virologic suppression was

maintained, the TIVICAY + ABC/3TC arm (80%) was superior to the EFV/TDF/FTC arm (72%), treatment difference was 8.0 (2.3, 13.8), $p=0.006$. The adjusted mean change in CD4+ T cell count from baseline were 267 cells/mm³ in the group receiving TIVICAY + ABC/3TC and 208 cells/mm³ for the EFV/TDF/FTC arm in SINGLE at 48 weeks. The adjusted difference and 95% CI was 58.9 (33.4, 84.4), $p<0.001$ (repeated measure model adjusting for the baseline stratification factors: baseline HIV-1 RNA and baseline CD4+ T cell count, among other factors). This analysis was pre-specified and adjusted for multiplicity. The median time to viral suppression was 28 days in the group receiving TIVICAY + ABC/3TC and 84 days in the EFV/TDF/FTC arm in SINGLE at 48 weeks ($p<0.0001$). This analysis was pre-specified and adjusted for multiplicity. At 144 weeks in the open-label phase, virologic suppression was maintained, the TIVICAY + ABC/3TC arm (71%) was superior to the EFV/TDF/FTC arm (63%), treatment difference was 8.3 (2.0, 14.6).

In both SPRING-2 and SINGLE studies virologic suppression (HIV-1 RNA <50 copies/mL), treatment differences were comparable across baseline characteristics (gender, race and age).

Through 96 weeks in SINGLE and SPRING-2, no INI-resistant mutations or treatment emergent resistance in background therapy were isolated on the TIVICAY-containing arms. In SPRING-2, four patients on the raltegravir arm failed with major NRTI mutations and one patients developed raltegravir resistance; in SINGLE, six patients on the EFV/TDF/FTC arm failed with mutations associated with NNRTI resistance and one developed a major NRTI mutation.

In FLAMINGO (ING114915), an open-label and active-controlled study, 484 HIV-1 infected antiretroviral naïve adults were randomized and received one dose of either TIVICAY 50 mg once daily or darunavir/ritonavir (DRV/r) 800 mg/100 mg once daily, both administered with fixed-dose dual NRTI therapy (either ABC/3TC or TDF/FTC). At baseline, median patient age was 34 years, 15% were female, 28% non-white, 10% had hepatitis B and/or C co-infection, and 3% were CDC Class C; these characteristics were similar between treatment groups. Virologic suppression (HIV-1 RNA <50 copies/mL) in the TIVICAY group (90%) was superior to the DRV/r group (83%) at 48 weeks. The adjusted difference in proportion and 95% CI were 7.1% (0.9, 13.2), $p=0.025$. At 96 weeks virologic suppression in the dolutegravir group (80%) was superior to the DRV/r group (68%). No treatment-emergent primary INI, PI or NRTI resistance mutations were observed for patients in the dolutegravir or DRV+RTV treatment groups.

Sustained virological response was demonstrated in the SPRING-1 study (ING112276), in which 88% of patients receiving TIVICAY 50 mg (n=51) once daily had HIV-1 RNA <50 copies/mL, compared to 72% of patients in the efavirenz group (n=50) at 96 weeks. No INI-resistant mutations or treatment emergent resistance in background therapy were isolated with TIVICAY 50 mg once daily through 96 weeks.

In GEMINI-1 (204861) and GEMINI-2 (205543), identical 148-week, randomised, double-blind, multicentre, non-inferiority studies, 1433 adult HIV-1 infected antiretroviral naïve subjects were randomised and received a two-drug regimen TIVICAY 50 mg plus lamivudine 300 mg once daily or TIVICAY 50 mg once daily with fixed dose tenofovir/emtricitabine (TDF/FTC). Subjects were enrolled with a screening plasma HIV-1 RNA of 1000 c/mL to $\leq 500,000$ c/mL. At baseline, in the pooled analysis of all patients, median patient age was

33 years, 15% were female, 31% non-white, 6% had hepatitis C co-infection and 9% were CDC Stage 3; these characteristics were similar between treatment groups.

Virologic suppression (HIV-1 RNA <50 copies/mL) in the TIVICAY plus lamivudine group (91% [pooled data]) was non-inferior to the TIVICAY plus TDF/FTC group (93% [pooled data]) at 48 weeks. The adjusted difference in proportion and 95% CI were -1.7% (-4.4, 1.1). The results of the pooled analysis were in line with those of the individual studies, for which the primary endpoint (difference in proportion <50 copies/mL plasma HIV-1 RNA at week 48 based on the Snapshot algorithm for TIVICAY plus lamivudine versus TIVICAY plus TDF/FTC) was met. The adjusted difference was -2.6% (95% CI: -6.7, 1.5) for GEMINI-1 and -0.7% (95% CI: -4.3, 2.9) for GEMINI-2 with a prespecified non-inferiority margin of 10%.

At 96 weeks the dolutegravir plus lamivudine group (86% with plasma HIV-1 RNA < 50 copies/mL [pooled data]) remained non-inferior to the dolutegravir plus tenofovir/emtricitabine FDC group (90% with plasma HIV-1 RNA < 50 copies/mL [pooled data]). The adjusted difference in proportions and 95% CI was -3.4% (-6.7, 0.0). The results of the pooled analysis were in line with those of the individual studies, for which the secondary endpoint (difference in proportion <50 copies/mL plasma HIV-1 RNA at Week 96 based on the Snapshot algorithm for dolutegravir plus lamivudine versus dolutegravir plus tenofovir/emtricitabine FDC) was met. The adjusted differences of -4.9 (95% CI: -9.8, 0.0) for GEMINI-1 and -1.8 (95% CI: -6.4, 2.7) for GEMINI-2 were within the prespecified non-inferiority margin of -10%. The mean increase in CD4+ T-cell counts was 269 cells/mm³ in the DTG+3TC arm and 259 cells/mm³ in the DTG+FTC/TDF arm, at week 96.

At 144 weeks in the GEMINI-1 and GEMINI-2 studies, the dolutegravir plus lamivudine group (82% with plasma HIV-1 RNA < 50 copies/mL [pooled data]) remained non-inferior to the dolutegravir plus tenofovir/emtricitabine FDC group (84% with plasma HIV-1 RNA < 50 copies/mL [pooled data]). The results of the pooled analysis were in line with those of the individual studies, for which the secondary endpoint (difference in proportion < 50 copies/mL plasma HIV-1 RNA at Week 144 based on the Snapshot algorithm for dolutegravir plus lamivudine versus dolutegravir plus tenofovir/emtricitabine FDC) was met. The adjusted difference in proportions and 95% CI was -1.8% (-5.8, 2.1). The adjusted differences of -3.6 (95% CI: -9.4, 2.1) for GEMINI-1 and 0.0 (95% CI: -5.3, 5.3) for GEMINI-2 were within the pre-specified non-inferiority margin of -10%. The mean increase in CD4+ T-cell counts was 302 cells/mm³ in the DTG+3TC arm and 300 cells/mm³ in the DTG+FTC/TDF arm, at Week 144. Through 144 weeks in the GEMINI-1 and GEMINI-2 studies, no subjects that met the protocol-defined confirmed virologic withdrawal criteria (CVW) had emergent integrase- or NRTI-class resistance substitutions.

There are no data available on the use of TIVICAY plus lamivudine as a two-drug regimen in paediatric patients.

Antiretroviral experienced (and integrase inhibitor naïve) patients

In the international, multicentre, double-blind SAILING study (ING111762), 719 HIV-1 infected, ART-experienced adults were randomised and received either TIVICAY 50 mg once daily or raltegravir 400 mg twice daily with investigator selected background regimen (BR) consisting of up to 2 agents (including at least one fully active agent). At baseline, median patient age was 43 years, 32% were female, 50% non-white, 16% had hepatitis B

and/or C co-infection, and 46% were CDC Class C. All patients had at least two class ART resistance, and 49% of patients had at least 3-class ART resistance at baseline.

Week 48 outcomes (including outcomes by key baseline covariates) for SAILING are shown in Table 5.

Table 5 Virologic Outcomes of Randomised Treatment of SAILING at 48 Weeks (Snapshot algorithm)

	SAILING	
	TIVICAY 50 mg Once Daily + BR N=354§	RAL 400 mg Twice Daily + BR N=361§
HIV-1 RNA <50 copies/mL	71%	64%
Adjusted Treatment Difference‡	7.4% (95% CI: 0.7%, 14.2%) P=0.003	
Virologic non response	20%	28%
No virologic data at Week 48	9%	9%
<u>Reasons</u>		
Discontinued study/study drug due to adverse event or death‡	3%	4%
Discontinued study/study drug for other reason§	5%	4%
Missing data during window but on study	2%	1%
HIV-1 RNA <50 copies/mL by baseline covariates		
Baseline Plasma Viral Load (copies/mL)	n / N (%)	n / N (%)
≤50,000 copies/mL	186 / 249 (75%)	180 / 254 (71%)
>50,000 copies/mL	65 / 105 (62%)	50 / 107 (47%)
Baseline CD4+ (cells/ mm³)		
<50	33 / 62 (53%)	30 / 59 (51%)
50 to <200	77 / 111 (69%)	76 / 125 (61%)
200 to <350	64 / 82 (78%)	53 / 79 (67%)
≥350	77 / 99 (78%)	71 / 98 (73%)
Background Regimen		
Phenotypic Susceptibility Score* <2	70 / 104 (67%)	61 / 94 (65%)
Phenotypic Susceptibility Score* =2	181 / 250 (72%)	169 / 267 (63%)
Genotypic Susceptibility Score* <2	155 / 216 (72%)	129 / 192 (67%)
Genotypic Susceptibility Score* =2	96 / 138 (70%)	101 / 169 (60%)
DRV/r in BR		
No DRV/r use		
DRV/r use with Primary PI mutations	143/214 (67%)	126/209 (60%)
DRV/r use without Primary PI	58/68 (85%)	50/75 (67%)
	50/72 (69%)	54/77 (70%)
Gender		
Male	172 / 247 (70%)	156 / 238 (66%)
Female	79 / 107 (74%)	74 / 123 (60%)
Race		
White	133 / 178 (75%)	125 / 175 (71%)
African-America/African Heritage/Other	118 / 175 (67%)	105 / 185 (57%)
Age (years)		
<50	196 / 269 (73%)	172 / 277 (62%)
≥50	55 / 85 (65%)	58 / 84 (69%)
HIV sub type		
Clade B	173 / 241 (72%)	159 / 246 (65%)
Clade C	34 / 55 (62%)	29 / 48 (60%)
Other†	43 / 57 (75%)	42 / 67 (63%)

	SAILING	
	TIVICAY 50 mg Once Daily + BR N=354§	RAL 400 mg Twice Daily + BR N=361§
‡ Adjusted for baseline stratification factors § 4 patients were excluded from the efficacy analysis due to data integrity at one study site *The Phenotypic Susceptibility Score (PSS) and the Genotypic Susceptibility Score (GSS) were defined as the total number of ARTs in BR to which a patient's viral isolate showed susceptibility at baseline based upon phenotypic or genotypic resistance tests. Background regimen was restricted to ≤ 2 ART with at least one fully active agent, however, n=11 PSS 0, n=2 PSS 3. †Other clades included: Complex (43), F1 (32), A1 (18), BF (14), all others <10. Notes: BR = background regimen, RAL = raltegravir; N = Number of patients in each treatment group.		

In the SAILING study, virologic suppression (HIV-1 RNA <50 copies/mL) in the dolutegravir arm (71%) was statistically superior to the raltegravir arm (64%), at Week 48 (p=0.030). Virologic suppression (HIV-1 RNA <50 copies/mL) treatment differences were comparable across the baseline characteristics of gender, race, and HIV sub type. The mean changes in CD4+ T cell count from baseline were 113 cells/mm³ at week 24 and 162 cells/mm³ at week 48 in the group receiving TIVICAY; and 106 cells/mm³ at week 24 and 153 cells/mm³ at week 48 for the raltegravir group.

Statistically fewer patients failed therapy with treatment-emergent resistance in the IN gene on TIVICAY (4/354, 1%) than on raltegravir (17/361, 5%) (p=0.003).

Integrase inhibitor resistant patients

In the Phase IIb, international multicentre, open-label, single arm, non-comparative sequential cohort VIKING pilot study (ING112961), two sequential cohorts of patients with multiclass resistance including resistance to HIV integrase inhibitors were enrolled to examine the antiviral activity of TIVICAY 50 mg once daily (n=27) vs. 50 mg twice daily (n=24) after 10 days of functional monotherapy. Responses were greater with twice daily (1.8 log₁₀ change from baseline in HIV RNA) than with once daily dosing (1.5 log₁₀ change from baseline, adjusted difference 0.3 log₁₀, p=0.017). Higher response rates with twice daily dosing were maintained with continued TIVICAY dosing and optimization of the background regimen through 48 weeks of therapy (33% vs. 71% <50 c/mL, ITT-E TLOVR analysis). A comparable safety profile was observed across doses. Subsequently, VIKING-3 examined the effect of TIVICAY 50 mg twice daily over 7 days of functional monotherapy, followed by optimized background therapy and continued TIVICAY twice daily treatment.

In the multicentre, open-label, single arm, non-comparative VIKING-3 study (ING112574), HIV-1 infected, ART-experienced adults with virological failure and current or historical evidence of raltegravir and/or elvitegravir resistance received TIVICAY 50 mg twice daily with the current failing background regimen for 7 days but with optimised background ART from Day 8. One hundred and eighty-three patients enrolled, 133 with INI-resistance at Screening and 50 with only historical evidence of resistance (and not at Screening). At baseline, median patient age was 48 years, 23% were female, 29% non-white, and 20% had hepatitis B and/or C co-infection. Median baseline CD4 was 140 cells/mm³, median duration of prior ART was 14 years, and 56% were CDC Class C. Patients showed multiple class ART resistance at baseline: 79% had ≥2 NRTI, 75% ≥1 NNRTI, and 71% ≥2 PI major

mutations; 62% had non-R5 virus. The Virological Outcome (VO) population excluded patients who stopped therapy for non-efficacy reasons, and those with major protocol deviations (incorrect dolutegravir dosing, intake of prohibited co-medication). The VO population is a subset of the ITT-E population.

Mean change from baseline in HIV RNA at day 8 (primary endpoint) was $-1.4\log_{10}$ (95% CI $-1.3, -1.5\log_{10}$, $p < 0.001$). Response was associated with baseline INI mutation pathway, as shown in Table 6.

Table 6 Virologic Response (Plasma HIV-1 RNA) at Day 8 by Derived baseline IN Resistance Mutation Group [Day 8 Virologic Outcome (VO) Population]

Derived IN Mutation Group	Number of patients (VO population)	Mean Change from baseline (SD) at Day 8	%>1log ₁₀ decline at Day 8*
No Q148H/K/R mutations [#]	124	-1.60 (0.52)	92%
Q148 + 1 secondary mutation [^]	35	-1.18 (0.52)	71%
Q148 + ≥2 secondary mutations [^]	20	-0.92 (0.81)	45%
[#] Includes primary INI resistance mutations N155H, Y143C/H/R, T66A, E92Q, or historical evidence of INI resistance only [*] Includes patients with HIV RNA <50 copies/mL at Day 8 [^] G140A/C/S, E138A/K/T, L74I			

After the monotherapy phase, patients had the opportunity to re-optimize their background regimen when possible.

Of the 183 patients who completed 24 weeks on study or discontinued before data cut-off, 126 (69%) had <50 copies/mL RNA at Week 24 (ITT-E, Snapshot algorithm). Patients harbouring virus with Q148 with additional Q148-associated secondary mutations has lower response at Week 24. Background overall susceptibility score (OSS) was not associated with Week 24 response.

Table 7 Week 24 Virologic Response by Derived baseline IN Resistance Mutation Group and OSS of OBR (HIV-1 RNA <50 c/mL, Snapshot algorithm), Week 24 VO Population

Derived IN Mutation Group	OSS=0	OSS=1	OSS=2	OSS>2	Total
No Q148H/K/R mutations ¹	4/4 (100%)	35/40 (88%)	40/48 (83%)	17/22 (77%)	96/114 (84%)
Q148 + 1 secondary mutation ²	2/2 (100%)	8/12 (67%)	10/17 (59%)	-	20/31 (65%)
Q148 + ≥2 secondary mutations ²	1/2 (50%)	2/11 (18%)	1/3 (33%)	-	4/16 (25%)
¹ N155H, Y143C/H/R, T66A, E92Q, or historical evidence of INI resistance only. ² G140A/C/S, E138A/K/T, L74I OSS: Overall susceptibility score [combined genotypic and phenotypic resistance (Monogram Biosciences Net Assessment)]					

The response rate at week 48 was sustained with 116/183 (63%) patients having HIV-1 RNA <50 copies/mL (ITT-E, Snapshot algorithm). Response was also sustained through week 48 in patients harbouring virus with Q148 with additional Q148-associated secondary mutations. The proportion of patients with HIV RNA <50 copies/mL at Week 48 was 88/113 (78%) for No Q148 mutations, 19/31 (61%) for Q148+1 and 4/16(25%) for Q148+≥2 secondary mutations (VO population, Snapshot algorithm). Background overall susceptibility score (OSS) was not associated with Week 48 response.

Virologic suppression (HIV-1 RNA <50 copies/mL) was comparable across baseline characteristics (gender, race and age). The median change in CD4+ T cell count from baseline for VIKING-3 based on observed data was 61 cells/mm³ at Week 24 and 110 cells/mm³ at Week 48.

In the multicentre, double blind, placebo controlled VIKING-4 study (ING116529), 30 HIV-1 infected, ART-experienced adults with current virological failure on an integrase inhibitor containing regimen and primary genotypic resistance to INIs at Screening, were randomised to receive either TIVICAY 50 mg twice daily or placebo with the current failing regimen for 7 days with all patients receiving open label TIVICAY plus optimised background regimen from Day 8. At baseline, median patient age was 49 years, 20% were female, 58% non-white, and 23% had hepatitis B and/or C co-infection. Median baseline CD4+ was 160 cells/mm³, median duration of prior ART was 13 years, and 63% were CDC Class C. Patients showed multiple class ART resistance at baseline: 80% had ≥2 NRTI, 73% ≥1 NNRTI, and 67% ≥2 PI major mutations; 83% had non-R5 virus. Sixteen of 30 patients (53%) harboured Q148 virus at baseline. The primary endpoint treatment comparison at Day 8, showed that TIVICAY 50 mg twice daily was superior to placebo, with an adjusted mean treatment difference for the change from Baseline in Plasma HIV-1 RNA at Day 8 of -1.2 log₁₀ copies/mL (95% CI -1.5, -0.8 log₁₀ copies/mL, p<0.001). The day 8 responses in this placebo controlled study were consistent with those seen in VIKING-3, including by baseline integrase resistance categories. At week 48, 12/30 (40%) patients had HIV-1 RNA <50 copies/mL (ITT-E, Snapshot algorithm).

In a combined analysis of VIKING-3 and VIKING-4 (n=186, VO population), the proportion of patients with HIV RNA <50 copies/mL at Week 48 was 123/186 (66%). The proportion of patients with HIV RNA <50 copies/mL was 96/126 (76%) for No Q148 mutations, 22/41 (54%) for Q148+1 and 5/19 (26%) for Q148+≥2 secondary mutations.

Virologically suppressed patients

The efficacy of TIVICAY plus rilpivirine is supported by data from 2 randomised, open-label, controlled trials (SWORD-1 [201636] and SWORD-2 [201637]) in virologically suppressed patients switching from their current antiretroviral regimen (CAR).

SWORD-1 and SWORD-2 are identical 148-week, Phase III, randomised, multicentre, parallel-group, non-inferiority studies. A total of 1,024 adult HIV-1 infected subjects who were on a stable suppressive antiretroviral regimen (containing 2 NRTIs plus either an INI, an NNRTI, or a PI) received treatment in the studies. Subjects were randomised 1:1 to continue their CAR or be switched to a two-drug regimen TIVICAY plus rilpivirine administered once daily. At Week 52, subjects who were originally assigned to continue their CAR and remained virologically suppressed switched to TIVICAY plus rilpivirine. The

primary efficacy endpoint for the SWORD studies was the proportion of subjects with plasma HIV-1 RNA <50 copies/mL at Week 48 (Snapshot algorithm for the ITT-E population).

At baseline, in the pooled analysis, the median age of subjects was 43 years, 22% female, 20% non-white, 11% were CDC Class C (AIDS), and 11% had CD4+ cell count less than 350 cells per mm³; these characteristics were similar between treatment arms. In the pooled analysis, 54%, 26%, and 20% of subjects were receiving an NNRTI, PI, or INI (respectively) as their baseline third treatment agent class prior to randomisation and was similar between treatment arms.

The pooled primary analysis demonstrated that TIVICAY plus rilpivirine is non-inferior to CAR, with 95% of subjects in both arms achieving the primary endpoint of <50 copies/mL plasma HIV-1 RNA at Week 48 based on the Snapshot algorithm (Table 8).

The primary endpoint and other outcomes (including outcomes by key baseline covariates) for the pooled SWORD-1 and SWORD-2 studies are shown in Table 8.

Table 8 Virologic Outcomes of Randomised Treatment for Virologically Suppressed Subjects at Week 48 (Snapshot algorithm)

	SWORD-1 and SWORD-2 Pooled Data	
	TIVICAY (DTG + RPV) N=513	CAR N=511
HIV-1 RNA <50 copies/mL	95%	95%
Treatment Difference*	-0.2 (-3.0, 2.5)	
Virologic non response†	<1%	1%
Reasons		
Data in window not <50 copies/mL	0	<1%
Discontinued for lack of efficacy	<1%	<1%
Discontinued for other reasons while not <50 copies/mL	<1%	<1%
Change in ART	0	<1%
No virologic data at Week 48 window	5%	4%
Reasons		
Discontinued study/study drug due to adverse event or death	3%	<1%
Discontinued study/study drug for other reasons	1%	3%
Missing data during window but on study	0	<1%
HIV-1 RNA <50 copies/mL by baseline covariates		
	n/N (%)	n/N (%)
Baseline CD4+ (cells/ mm³)		
<350	51 / 58 (88%)	46 / 52 (88%)
≥350	435 / 455 (96%)	439 / 459 (96%)
Baseline Third Treatment Agent Class		
INSTI	99 / 105 (94%)	92 / 97 (95%)
NNRTI	263 / 275 (96%)	265 / 278 (95%)
PI	124 / 133 (93%)	128 / 136 (94%)
Gender		
Male	375 / 393 (95%)	387 / 403 (96%)
Female	111 / 120 (93%)	98 / 108 (91%)
Race		
White	395 / 421 (94%)	380 / 400 (95%)
African-America/African Heritage/Other	91/92 (99%)	105 / 111 (95%)
Age (years)		
<50	350 / 366 (96%)	348 / 369 (94%)
≥50	136 / 147 (93%)	137 / 142 (96%)
<p>* Adjusted for baseline stratification factors and assessed using a non-inferiority margin of -8%. † Non-inferiority of DTG + RPV to CAR in the proportion of subjects classified as virologic non-responders was demonstrated using a non-inferiority margin of 4%. Adjusted difference (95% CI) -0.6 (-1.7, 0.6). N = Number of subjects in each treatment group INSTI = Integrase inhibitor; NNRTI = Non-nucleoside reverse transcriptase inhibitor; PI = Protease Inhibitor DTG+RPV = dolutegravir plus rilpivirine CAR = current antiretroviral regimen</p>		

At Week 148 in the pooled SWORD-1 and SWORD-2 trials, 84% of subjects who received dolutegravir plus rilpivirine as of study start had plasma HIV-1 RNA < 50 copies/mL based on the Snapshot algorithm. In subjects who initially remained on their CAR and switched to dolutegravir plus rilpivirine at Week 52, 90% had plasma HIV-1 RNA < 50 copies/mL at Week 148 based on the Snapshot algorithm, which was comparable to the response rate

(89%) observed at Week 100 (similar exposure duration) in subjects receiving dolutegravir plus rilpivirine as of study start.

There are no clinical study data with TIVICAY plus rilpivirine in the paediatric population.

Antiretroviral Pregnancy Registry

The APR has received reports of over 1,300 exposures to dolutegravir during pregnancy resulting in live births. These consist of over 870 exposures during the first trimester, over 500 exposures during the second/third trimester and included 29 and 25 birth defects, respectively. The prevalence (95% CI) of defects among live births exposed to dolutegravir in the first trimester was 3.3% (2.2%, 4.7%) and in the second/third trimester, 5.0% (3.2%, 7.3%).

The available data from the APR shows no significant increase in risk of major birth defects for dolutegravir compared to the background rates in the two population based surveillance systems (Metropolitan Atlanta Congenital Defects Program with defects of 2.72 per 100 live births and the Texas Birth Defects Registry with 4.17 per 100 live births).

Paediatric population

In a Phase I/II 48 week multicentre, open-label study (P1093/ING112578), the pharmacokinetic parameters, safety, tolerability and efficacy of TIVICAY was evaluated in combination regimens in HIV-1 infected infants, children and adolescents.

At 24 weeks, 16 of 23 (70%) children and adolescents (12 to less than 18 years of age) treated with TIVICAY once daily (35 mg n=4, 50 mg n=19) plus OBR achieved viral load less than 50 copies/mL. Twenty out of 23 children and adolescents (87%) had >1 log₁₀ c/mL decrease from Baseline in HIV-1 RNA or HIV-1 RNA <400 c/mL at Week 24.

Four patients had virologic failure none of which had INI resistance at the time of virologic failure.

5.2 Pharmacokinetic properties

Dolutegravir pharmacokinetics is similar between healthy and HIV-infected patients. The PK variability of dolutegravir is between low to moderate. In Phase 1 studies in healthy patients, between-patient CVb% for AUC and C_{max} ranged from ~20 to 40% and C_τ from 30 to 65% across studies. The between-patient PK variability of dolutegravir was higher in HIV-infected patients than healthy patients and CVb% was estimated to be 30-50% for AUC and C_{max}, and at 55-140% for C_τ. Within-patient variability (CVw%) is lower than between-patient variability.

Absorption

Dolutegravir is rapidly absorbed following oral administration, with median T_{max} at 2 to 3 hours post dose for tablet formulation. The linearity of dolutegravir pharmacokinetics is dependent on dose and formulation. Following oral administration of tablet formulations, in general, dolutegravir exhibited nonlinear pharmacokinetics with less than dose-proportional increases in plasma exposure from 2 to 100 mg; however increase in dolutegravir exposure appears dose proportional from 25 mg to 50 mg.

Dolutegravir may be administered with or without food. Food increased the extent and slowed the rate of absorption of dolutegravir. Bioavailability of dolutegravir depends on meal content: low, moderate, and high fat meals increased dolutegravir AUC_(0-∞) by 33%, 41%, and 66%, increased C_{max} by 46%, 52%, and 67%, prolonged T_{max} to 3, 4, and 5 hours from 2 hours under fasted conditions, respectively. These increases are not clinically significant.

The absolute bioavailability of dolutegravir has not been established.

Distribution

Dolutegravir is highly bound (approximately 99.3%) to human plasma proteins based on in vitro data. The apparent volume of distribution (following oral administration of suspension formulation, Vd/F) is estimated at 12.5 L. Binding of dolutegravir to plasma proteins was independent of concentration. Total blood and plasma drug-related radioactivity concentration ratios averaged between 0.441 to 0.535, indicating minimal association of radioactivity with blood cellular components. Free fraction of dolutegravir in plasma is estimated at approximately 0.2 to 1.1% in healthy patients, approximately 0.4 to 0.5% in patients with moderate hepatic impairment, and 0.8 to 1.0% in patients with severe renal impairment and 0.5% in HIV-1 infected patients.

Dolutegravir is present in cerebrospinal fluid (CSF). In 12 treatment-naïve patients receiving a regimen of dolutegravir plus abacavir/lamivudine (3TC) for 16 weeks, dolutegravir concentration in CSF averaged 15.4 ng/mL at Week 2 and 12.6 ng/mL at Week 16, ranging from 3.7 to 23.2 ng/mL (comparable to unbound plasma concentration). CSF:plasma concentration ratio of dolutegravir ranged from 0.11 to 2.04%. Dolutegravir concentrations in CSF exceeded the IC₅₀, supporting the median reduction from baseline in CSF HIV-1 RNA of 2.2 log after 2 weeks and 3.4 log after 16 weeks of therapy (see section 5.1 Pharmacodynamic properties).

Dolutegravir is present in the female and male genital tract. AUC in cervicovaginal fluid, cervical tissue, and vaginal tissue were 6 to 10% of that in corresponding plasma at steady-state. AUC was 7% in semen and 17% in rectal tissue, of those in corresponding plasma at steady-state.

Biotransformation

Dolutegravir is primarily metabolized via UGT1A1 with a minor CYP3A component (9.7% of total dose administered in a human mass balance study). Dolutegravir is the predominant circulating compound in plasma; renal elimination of unchanged drug is low (<1% of the dose). Fifty-three percent of total oral dose is excreted unchanged in the faeces. It is unknown if all or part of this is due to unabsorbed drug or biliary excretion of the glucuronide conjugate, which can be further degraded to form the parent compound in the gut lumen. Thirty-one percent of the total oral dose is excreted in the urine, represented by ether glucuronide of dolutegravir (18.9% of total dose), N-dealkylation metabolite (3.6% of total dose), and a metabolite formed by oxidation at the benzylic carbon (3.0% of total dose).

Elimination

Dolutegravir has a terminal half-life of ~14 hours and an apparent clearance (CL/F) of 0.56 L/hr.

Special populations

Paediatric population

In a paediatric study including 23 antiretroviral treatment-experienced HIV-1 infected adolescents aged 12 to 18 years of age, the pharmacokinetics of dolutegravir was evaluated in 10 adolescents and showed that dolutegravir 50 mg once daily dosage resulted in dolutegravir exposure in paediatric patients comparable to that observed in adults who received dolutegravir 50 mg once daily (Table 9).

Table 9 Paediatric pharmacokinetic parameters (n=10)

Age/weight	Dolutegravir Dose	Dolutegravir Pharmacokinetic Parameter Estimates		
		Geometric Mean (CV%)		
		AUC ₍₀₋₂₄₎ µg.hr/mL	C _{max} µg/mL	C ₂₄ µg/mL
12 to 18 years ≥ 40 kg ^a	50 mg once daily ^a	46 (43)	3.49 (38)	0.90 (59)

^a One patient weighing 37 kg received 35 mg once daily.

Elderly

Population pharmacokinetic analysis of dolutegravir using data in HIV-1 infected adults showed that there was no clinically relevant effect of age on dolutegravir exposure.

Pharmacokinetic data for dolutegravir in patients of >65 years old are limited.

Renal impairment

Renal clearance of unchanged drug is a minor pathway of elimination for dolutegravir. A study of the pharmacokinetics of dolutegravir was performed in patients with severe renal impairment (CrCl <30 mL/min). No clinically important pharmacokinetic differences between patients with severe renal impairment (CrCl <30 mL/min) and matching healthy patients were observed. No dosage adjustment is necessary for patients with renal impairment. Caution is warranted for INI-experienced patients (with certain INI-associated resistance substitutions or clinically suspected INI resistance) with severe renal impairment, as the decrease in dolutegravir concentrations may result in loss of therapeutic effect and development of resistance to dolutegravir or other co-administered antiretroviral agents. There is limited information on dolutegravir in patients on dialysis, though differences in exposure are not expected.

Hepatic impairment

Dolutegravir is primarily metabolized and eliminated by the liver. In a study comparing 8 patients with moderate hepatic impairment (Child-Pugh category B) to 8 matched healthy adult controls, the single 50 mg dose exposure of dolutegravir was similar between the two groups. No dosage adjustment is necessary for patients with mild to moderate hepatic impairment. The effect of severe hepatic impairment on the pharmacokinetics of dolutegravir has not been studied.

Polymorphisms in drug metabolising enzymes

There is no evidence that common polymorphisms in drug metabolising enzymes alter dolutegravir pharmacokinetics to a clinically meaningful extent. In a meta-analysis using pharmacogenomic samples collected in clinical studies in healthy patients, patients with UGT1A1 (n=7) genotypes conferring poor dolutegravir metabolism had a 32% lower clearance of dolutegravir and 46% higher AUC compared with patients with genotypes associated with normal metabolism via UGT1A1 (n=41). Polymorphisms in CYP3A4, CYP3A5, and NR1I2 were not associated with differences in the pharmacokinetics of dolutegravir.

Gender

The dolutegravir exposure in healthy patients appear to be slightly higher (~20%) in women than men based on data obtained in a healthy patient study (males n=17, females n=24). Population PK analyses using pooled pharmacokinetic data from Phase IIb and Phase III adult trials revealed no clinically relevant effect of gender on the exposure of dolutegravir.

Race

Population PK analyses using pooled pharmacokinetic data from Phase IIb and Phase III adult trials revealed no clinically relevant effect of race on the exposure of dolutegravir. The pharmacokinetics of dolutegravir following single dose oral administration to Japanese patients appear similar to observed parameters in Western (US) patients.

Co-infection with Hepatitis B or C

Population pharmacokinetic analysis indicated that hepatitis C virus co-infection had no clinically relevant effect on the exposure to dolutegravir. There are limited data on patients with hepatitis B co-infection.

5.3 Preclinical safety data

Genotoxicity

Dolutegravir was not mutagenic or clastogenic using in vitro tests in bacteria and cultured mammalian cells, and an in vivo rodent micronucleus assay.

Carcinogenicity

In long-term oral carcinogenicity studies conducted with dolutegravir no drug-related increases in tumour incidence were found in mice at doses up to 500 mg/kg/day (14 times the human systemic exposure based on AUC at the maximum recommended dose of 50 mg BID) or in rats at doses up to 50 mg/kg/day (12 times the human systemic exposure based on AUC at the maximum recommended dose).

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Mannitol

Microcrystalline cellulose

Povidone

Sodium starch glycolate Type A

Sodium stearyl fumarate

Polyvinyl alcohol – part hydrolyzed

Titanium dioxide

Macrogol 3350

Talc

Iron oxide yellow.

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

60 months from date of manufacture.

6.4 Special precautions for storage

Store below 30°C.

6.5 Nature and contents of container

TIVICAY tablets are supplied in HDPE (high density polyethylene) bottles containing 30 tablets.

6.6 Special precautions for disposal

No special requirements.

7. MEDICINE SCHEDULE

Prescription Medicine

8. SPONSOR

GlaxoSmithKline (NZ) Ltd
Private Bag 106600
Downtown
Auckland
New Zealand

Phone: (09) 367 2900
Facsimile: (09) 367 2910

9. DATE OF FIRST APPROVAL

28 August 2014

10. DATE OF REVISION OF THE TEXT

5 May 2025

SUMMARY TABLE OF CHANGES

Section changed	Summary of new information
4.6	Update to information regarding dolutegravir use in pregnancy and breast feeding
5.1	Update to Antiretroviral Pregnancy Registry data
4.8	Sideroblastic Anaemia is included as an undesirable effect under 'Post-marketing data'.

Trade marks are owned by or licensed to the ViiV Healthcare group of companies.

© 2025 ViiV Healthcare group of companies or its licensor.

Version 15.0